How Do I Read an MDS Bone Marrow Biopsy Report Clearly?

When you look at your bone marrow biopsy report for Myelodysplastic Syndromes (MDS), you will likely see four key terms: cellularity, dysplasia, ring sideroblasts, and blasts. Together, these findings are some of the features used to classify your disease and estimate your risk. However, no single number can give you the full picture, and reading these reports can be overwhelming. These physical findings must always be interpreted alongside your blood counts, genetic testing, and your overall health ^[1][2].

Understanding Your Sample

A bone marrow evaluation usually involves two parts, and your report will indicate which specimen was used for which finding ^[3]:

• The Core Biopsy: A solid piece of bone and marrow, primarily used to assess overall cellularity and marrow architecture.
• The Aspirate Smear: The liquid portion of the marrow, used to count blasts, evaluate dysplasia, and look for ring sideroblasts using an iron stain.

If your report notes that the aspirate was “hemodilute” (diluted with regular blood) or “inadequate,” it means the sample was less than ideal, which can make percentages harder to accurately count ^[4].

Cellularity: How “Full” is Your Factory?

Cellularity refers to the percentage of your bone marrow space that is filled with blood-forming cells compared to empty fat cells ^[5]. Think of your bone marrow as a factory; cellularity measures how many active workers are inside.

• The “100-Minus-Age” Rule: A common, older rule of thumb estimates expected cellularity by subtracting your age from 100.
• A Rough Estimate: However, this is not a strict target. Recent studies show that normal cellularity has a very wide range and doesn’t drop off quite as sharply with age as the rule suggests ^[5][6].

In MDS, the marrow is often hypercellular (overcrowded with cells). Even though there are many cells, they may mature abnormally or be lost in the marrow before producing enough healthy circulating blood cells ^[3]. Sometimes, the marrow is hypocellular (too empty). A hypocellular marrow can make MDS harder to distinguish from other bone marrow failure conditions like aplastic anemia ^[7][8].

Dysplasia: Abnormal Looking Cells

Dysplasia means that the blood-forming cells look abnormal in their shape, size, or structure under a microscope ^[9].

• Pathologists look at three main families of marrow cells: erythroid (red blood cell precursors), granulocytic/myeloid (white blood cell precursors), and megakaryocytic (the cells that produce platelets) ^[9].
• Significant dysplasia is usually reported as a diagnostic feature when at least 10% of the cells in a specific lineage look abnormal ^[9].

While 10% is a key diagnostic threshold, seeing dysplasia does not automatically confirm MDS. Vitamin deficiencies (such as B12 or copper), medication side effects, or toxins can also cause cells to look dysplastic ^[10]. Your doctor must rule out these other causes first.

Ring Sideroblasts: Iron-Laden Precursor Cells

Ring sideroblasts are immature red blood cells that have an abnormal ring of iron trapped in their mitochondria (the energy centers around the cell’s nucleus) ^[11]. Note: Having ring sideroblasts does not mean you have systemic iron overload throughout your entire body.

• They are strongly linked to a specific genetic mutation called SF3B1 ^[12].
• While an SF3B1 mutation and ring sideroblasts can be a favorable finding associated with slower progression in some settings, it is not a guarantee. Prognosis also depends heavily on your blast percentage, other mutations, and blood counts ^[13][14].
• Some patients with this specific subtype may be candidates for targeted anemia treatments (like luspatercept), though eligibility and response will vary ^[14].

Blasts: Immature Precursor Cells

Blasts are very young, immature blood cells. In a healthy person, blasts make up fewer than 5% of the cells in the bone marrow and are rarely seen in the circulating blood ^[15].

• In MDS, these blasts fail to mature properly and can start to build up.
• The blast percentage is a major factor in determining your risk level. A higher percentage generally contributes to a higher-risk category, but small changes (like moving from 4% to 6%) might simply reflect sampling variation rather than true disease progression ^[15].

MDS vs. AML: Medical classification systems use blasts to help define the disease, but they differ slightly. The World Health Organization (WHO) uses a 20% blast threshold for distinguishing MDS from Acute Myeloid Leukemia (AML). Meanwhile, the International Consensus Classification (ICC) uses a 10% threshold to define a transitional “MDS/AML” category ^[16][17]. Therefore, having 10% blasts does not universally mean you have AML; the exact label depends on which system your hematologist uses, your genetics, and other findings.

The Importance of Context and Risk Scoring

None of these four factors stand alone. To accurately diagnose your MDS and calculate an overall risk score (like the IPSS-R or the newer molecular IPSS-M), your doctor combines these visual marrow findings with:

• Cytogenetics: Looking for large-scale chromosome changes, such as del(5q) ^[18].
• Next-Generation Sequencing (NGS): Checking for specific DNA mutations at the molecular level, such as SF3B1 or TP53 ^[1][19]. Finding a mutation alone does not diagnose MDS, as mutations can occur in healthy aging people (a condition called clonal hematopoiesis); they must be interpreted in context ^[20].
• Blood Counts: Evaluating the severity of your low red cells, white cells, and platelets ^[1].

This complete picture determines your unique MDS subtype, evaluates your risk, and guides your individualized treatment plan ^[21].

(Note: If you experience fever, significant new bleeding, or severe shortness of breath, contact your hematology team promptly. Bracketed codes like ^[1] refer to the specific medical literature sources used to ensure this guide is evidence-based.)